JPS6323882A - アヘンアルカロイドおよびそれらの代謝物のための免疫検定法、トレ−サ−、免疫原および抗体 - Google Patents

アヘンアルカロイドおよびそれらの代謝物のための免疫検定法、トレ−サ−、免疫原および抗体

Info

Publication number: JPS6323882A
Authority: JP; Japan
Prior art keywords: hydrogen; formula; hydroxy; tables; formulas
Prior art date: 1986-07-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP62174025A

Other languages

English (en)

Japanese (ja)

Inventor

ダニエル　フエルナー　ヘイマン

ダニエル　エス　ラデン

ロバート　エドワード　ダブラ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-14

Filing date

1987-07-14

Publication date

1988-02-01

1987-07-14 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

1988-02-01 Publication of JPS6323882A publication Critical patent/JPS6323882A/ja

Status Pending legal-status Critical Current

Links

239000008896 Opium Substances 0.000 title claims description 53
229960001027 opium Drugs 0.000 title claims description 53
229930013930 alkaloid Natural products 0.000 title claims description 38
-1 immunoassey Substances 0.000 title claims description 18
230000002163 immunogen Effects 0.000 title claims description 17
239000002207 metabolite Substances 0.000 title claims description 12
239000000700 radioactive tracer Substances 0.000 title description 46
229910052739 hydrogen Inorganic materials 0.000 claims description 70
239000001257 hydrogen Substances 0.000 claims description 69
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 42
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 41
238000000034 method Methods 0.000 claims description 37
150000001875 compounds Chemical class 0.000 claims description 35
239000000126 substance Substances 0.000 claims description 26
150000003797 alkaloid derivatives Chemical class 0.000 claims description 24
150000002431 hydrogen Chemical class 0.000 claims description 24
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 24
239000003153 chemical reaction reagent Substances 0.000 claims description 18
125000004432 carbon atom Chemical group C* 0.000 claims description 15
238000002875 fluorescence polarization Methods 0.000 claims description 12
229910052799 carbon Inorganic materials 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 11
150000002576 ketones Chemical class 0.000 claims description 11
125000005842 heteroatom Chemical group 0.000 claims description 9
102000004169 proteins and genes Human genes 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 7
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
229910052794 bromium Inorganic materials 0.000 claims description 7
239000000460 chlorine Substances 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
125000004093 cyano group Chemical group *C#N 0.000 claims description 7
239000011737 fluorine Substances 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
125000004430 oxygen atom Chemical group O* 0.000 claims description 7
125000001153 fluoro group Chemical group F* 0.000 claims description 6
108010053455 riboflavin-binding protein Proteins 0.000 claims description 6
239000012876 carrier material Substances 0.000 claims description 5
125000000524 functional group Chemical group 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000005647 linker group Chemical group 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
150000003973 alkyl amines Chemical class 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
239000007859 condensation product Substances 0.000 claims description 3
229930182480 glucuronide Natural products 0.000 claims description 3
150000008134 glucuronides Chemical class 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
229920001184 polypeptide Polymers 0.000 claims description 3
108090000765 processed proteins & peptides Proteins 0.000 claims description 3
102000004196 processed proteins & peptides Human genes 0.000 claims description 3
229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
239000012279 sodium borohydride Substances 0.000 claims description 2
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
230000001590 oxidative effect Effects 0.000 claims 2
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 2
235000001508 sulfur Nutrition 0.000 claims 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
238000003556 assay Methods 0.000 description 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
239000000523 sample Substances 0.000 description 22
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
239000000243 solution Substances 0.000 description 21
230000010287 polarization Effects 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
239000003446 ligand Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 12
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
238000003018 immunoassay Methods 0.000 description 10
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 10
229960002477 riboflavin Drugs 0.000 description 9
239000002151 riboflavin Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
239000002243 precursor Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
235000019192 riboflavin Nutrition 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
238000003756 stirring Methods 0.000 description 6
210000002700 urine Anatomy 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
150000001412 amines Chemical group 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
229940127240 opiate Drugs 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
241001494479 Pecora Species 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229960005181 morphine Drugs 0.000 description 4
239000012299 nitrogen atmosphere Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
108010044091 Globulins Proteins 0.000 description 3
102000006395 Globulins Human genes 0.000 description 3
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
GNJCUHZOSOYIEC-GAROZEBRSA-N Morphine-6-glucuronide Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)O)O[C@@H]1[C@]52CCN3C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O GNJCUHZOSOYIEC-GAROZEBRSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000027455 binding Effects 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000013024 dilution buffer Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000004817 gas chromatography Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229950004819 morphine glucuronide Drugs 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
102000006410 Apoproteins Human genes 0.000 description 2
108010083590 Apoproteins Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
150000007514 bases Chemical class 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
235000013877 carbamide Nutrition 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
229960002069 diamorphine Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
239000003039 volatile agent Substances 0.000 description 2
FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
YOAWSYSKQHLFPM-UHFFFAOYSA-N 5-amino-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(N)C=C21 YOAWSYSKQHLFPM-UHFFFAOYSA-N 0.000 description 1
GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000014824 Crystallins Human genes 0.000 description 1
108010064003 Crystallins Proteins 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical group NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
WAEXKFONHRHFBZ-ZXDZBKESSA-N Morphine-3-glucuronide Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WAEXKFONHRHFBZ-ZXDZBKESSA-N 0.000 description 1
240000000249 Morus alba Species 0.000 description 1
235000008708 Morus alba Nutrition 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000026251 Opioid-Related disease Diseases 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Chemical group NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Chemical group OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000011096 Papaver Nutrition 0.000 description 1
240000001090 Papaver somniferum Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
VXDSLUMUNWTSDB-UHFFFAOYSA-N acetic acid;chloroform;methanol Chemical compound OC.CC(O)=O.ClC(Cl)Cl VXDSLUMUNWTSDB-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
239000012491 analyte Substances 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical group 0.000 description 1
239000012320 chlorinating reagent Substances 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical group OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000004020 conductor Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
235000014103 egg white Nutrition 0.000 description 1
210000000969 egg white Anatomy 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
239000003292 glue Substances 0.000 description 1
239000002920 hazardous waste Substances 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229960003406 levorphanol Drugs 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229930013053 morphinan alkaloid Natural products 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
125000002560 nitrile group Chemical group 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
238000011909 oxidative ring-opening Methods 0.000 description 1
229960005118 oxymorphone Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000024053 secondary metabolic process Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
241000894007 species Species 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
150000003461 sulfonyl halides Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/80—Fluorescent dyes, e.g. rhodamine
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/805—Optical property
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Food Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Emergency Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Peptides Or Proteins (AREA)

JP62174025A 1986-07-14 1987-07-14 アヘンアルカロイドおよびそれらの代謝物のための免疫検定法、トレ−サ−、免疫原および抗体 Pending JPS6323882A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/885,054 US4939264A (en)	1986-07-14	1986-07-14	Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
US885054		1986-07-14

Publications (1)

Publication Number	Publication Date
JPS6323882A true JPS6323882A (ja)	1988-02-01

Family

ID=25386024

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62174025A Pending JPS6323882A (ja)	1986-07-14	1987-07-14	アヘンアルカロイドおよびそれらの代謝物のための免疫検定法、トレ−サ−、免疫原および抗体

Country Status (3)

Country	Link
US (2)	US4939264A (de)
EP (1)	EP0254120A3 (de)
JP (1)	JPS6323882A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010505923A (ja) *	2006-10-12	2010-02-25	ネオルフィ	新規なモルヒネ誘導体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5155212A (en) *	1986-05-21	1992-10-13	Abbott Laboratories	Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
US6472227B1 (en) *	1986-06-04	2002-10-29	Abbott Laboratories	Barbiturate assay, tracers, immunogens, antibodies and kit
ES2079368T3 (es) *	1988-10-28	1996-01-16	Abbott Lab	Metodo y reactivos para detectar anfetaminas y/o d-meta-anfetaminas en muestras biologicas.
US5262333A (en) *	1988-10-28	1993-11-16	Abbott Laboratories	Method and reagents for detecting amphetamine and/or D-methamphetamine in biological samples
US5248791A (en) *	1989-04-10	1993-09-28	Abbott Laboratories	Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay
US5101015A (en) *	1989-04-10	1992-03-31	Abbott Laboratories	Reagents for an amphetamine-class fluorescence polarization immunoassay
EP0392332A3 (de) *	1989-04-12	1992-01-08	F. Hoffmann-La Roche Ag	Fluoreszenzpolarisationsimmunoassay und Reagentien dafür
DE69116034T2 (de) *	1990-08-15	1996-06-20	Abbott Lab	Immunotestreagenzien und Verfahren zur Bestimmung von Cyclosporin
CA2132342A1 (en) *	1992-04-06	1993-10-14	Kenneth F. Buechler	Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US5492841A (en) *	1994-02-18	1996-02-20	E. I. Du Pont De Nemours And Company	Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5741715A (en) *	1995-05-30	1998-04-21	Roche Diagnostic Systems, Inc.	Quinidine immunoassay and reagents
CA2239957A1 (en) *	1995-12-22	1997-07-03	Abbott Laboratories	Fluorescence polarization immunoassay diagnostic method
US6558956B1 (en) *	1997-06-24	2003-05-06	The University Of Wyoming	Method and apparatus for detection of a controlled substance
US6391547B1 (en) *	1997-09-09	2002-05-21	Center For The Application Of Molecular Biology To International Agriculture	Microbial β-glucuronidase genes, gene products and uses thereof
US7087420B1 (en)	1997-07-17	2006-08-08	Cambia	Microbial β-glucuronidase genes, gene products and uses thereof
US7632651B2 (en)	1997-09-15	2009-12-15	Mds Analytical Technologies (Us) Inc.	Molecular modification assays
US7745142B2 (en)	1997-09-15	2010-06-29	Molecular Devices Corporation	Molecular modification assays
US7070921B2 (en)	2000-04-28	2006-07-04	Molecular Devices Corporation	Molecular modification assays
US6770488B1 (en)	1999-03-19	2004-08-03	The University Of Wyoming	Practical method and apparatus for analyte detection with colloidal particles
US6262265B1 (en) *	1999-06-18	2001-07-17	Microgenics Corporation	Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
JP4340437B2 (ja)	2000-10-31	2009-10-07	レンセラールポリテクニックインスティチュート	８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン
GB0130535D0 (en) *	2001-12-20	2002-02-06	Randox Lab Ltd	Haptens immunogens antibodies and conjugates to oxycodone and its metabolites
US7238791B1 (en) *	2005-12-16	2007-07-03	Roche Diagnostics Operations, Inc.	6-monoacetylmorphine derivatives useful in immunoassay
US9119848B2 (en)	2009-12-04	2015-09-01	Alkermes Pharma Ireland Limited	Morphinan derivatives for the treatment of drug overdose
AU2011232628B2 (en)	2010-03-22	2015-04-09	Rensselaer Polytechnic Institute	Morphinane derivatives containing a carboxamide group as opioid receptor ligands
HUE065427T2 (hu)	2010-08-23	2024-05-28	Alkermes Pharma Ireland Ltd	Eljárások antipszichotikum által indukált súlygyarapodás kezelésére
US9029543B2 (en)	2011-04-05	2015-05-12	Alkermes, Inc.	Process for the synthesis of quaternary amine compounds
SMT201700400T1 (it)	2011-06-29	2017-09-07	Alkermes Inc	Composti oppioidi ad azione periferica
US9211293B2 (en)	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
MX375348B (es)	2011-12-15	2025-03-06	Alkermes Pharma Ireland Ltd	Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
CA2911231C (en)	2013-05-24	2021-12-07	Alkermes Pharma Ireland Limited	Morphan and morphinan analogues, and methods of use
EP3003311A2 (de)	2013-05-24	2016-04-13	Alkermes Pharma Ireland Limited	Verfahren zur behandlung von symptomen für depression
WO2022101444A1 (en)	2020-11-12	2022-05-19	Alkermes Pharma Ireland Limited	Immediate release multilayer tablet
CN119827467B (zh) *	2025-01-10	2026-03-24	中国科学技术大学	酰亚胺类化合物用于阿片类毒品的光激活荧光检测方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3940475A (en) *	1970-06-11	1976-02-24	Biological Developments, Inc.	Radioimmune method of assaying quantitatively for a hapten
US4097586A (en) *	1970-06-11	1978-06-27	Biological Developments, Inc.	Immunochemical assay method
US3690834A (en) *	1971-01-11	1972-09-12	Syva Co	Ligand determination with spin labeled compounds by receptor displacement
US3709868A (en) *	1971-03-08	1973-01-09	Hoffmann La Roche	Opium alkaloid antigens and antibodies specific therefor
US3704282A (en) *	1971-04-09	1972-11-28	Sidney Spector	Catecholamine antigens and antibodies specific therefor
US3817837A (en) *	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US4022878A (en) *	1972-05-15	1977-05-10	Biological Developments, Inc.	Methods and compounds for producing specific antibodies
US3966764A (en) *	1972-07-10	1976-06-29	Syva Company	Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3867366A (en) *	1972-11-06	1975-02-18	Synvar Associates A K A Syva C	Opiate imidates and protein conjugates thereof
US3856469A (en) *	1973-01-02	1974-12-24	Syva Corp	Interferant removal from amphetamine immunoassay
US3972992A (en) *	1973-06-29	1976-08-03	Hoffmann-La Roche Inc.	Diagnostic test for opium alkaloids
US3998943A (en) *	1973-10-02	1976-12-21	Syva Company	Double receptor fluorescent immunoassay
US4255329A (en) *	1973-10-02	1981-03-10	Syva Company	Double receptor fluorescent immunoassay
US4199559A (en) *	1974-08-12	1980-04-22	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4064228A (en) *	1974-11-29	1977-12-20	Biological Developments, Inc.	Antigens and immunoassays for morphine and related 3-oxybenzomorphan compounds
JPS51101120A (en) *	1975-02-28	1976-09-07	Dai Ichi Kogyo Seiyaku Co Ltd	Kogen oyobi kotainoseiho
GB1595101A (en) *	1977-03-15	1981-08-05	Hoffmann La Roche	Enzyme modifier immunoassay
IT1079045B (it) *	1977-05-16	1985-05-08	Syva Co	Analisi imuunologica fluorescente a doppio ricettore
US4231750A (en) *	1977-12-13	1980-11-04	Diagnostic Reagents, Inc.	Methods for performing chemical assays using fluorescence and photon counting
US4329281A (en) *	1978-06-05	1982-05-11	Hoffmann-La Roche Inc.	Hapten compositions
US4213904A (en) *	1979-02-28	1980-07-22	Haugland Richard P	Fluorescent labeling reagents containing the fluorescein and eosin chromophores
US4588697A (en) *	1979-09-07	1986-05-13	Syntex (U.S.A.) Inc.	Method for performing fluorescent protein binding assay employing novel alkyl substituted fluorescent compounds and conjugates
US4351760A (en) *	1979-09-07	1982-09-28	Syva Company	Novel alkyl substituted fluorescent compounds and polyamino acid conjugates
US4481136A (en) *	1979-09-07	1984-11-06	Syva Company	Alkyl substituted fluorescent compounds and conjugates
US4420568A (en) *	1980-07-30	1983-12-13	Abbott Laboratories	Fluorescent polarization immunoassay utilizing substituted triazinylaminofluoresceins
CA1160626A (en) *	1980-07-30	1984-01-17	Stephen D. Stroupe	Biologically interesting compounds labeled with dichlorotriazinyl-aminofluorescein
US4593089A (en) *	1980-07-30	1986-06-03	Abbott Laboratories	Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
AU555213B2 (en) *	1981-02-17	1986-09-18	Abbott Laboratories	N-substituted-amido-fluoresein derivatives
US4668640A (en) *	1981-12-11	1987-05-26	Abbott Laboratories	Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4585862A (en) *	1981-12-11	1986-04-29	Abbott Laboratories	Fluorescence polarization immunoassay
US4492762A (en) *	1981-12-11	1985-01-08	Abbott Laboratories	Fluorescent polarization immunoassays
US4476228A (en) *	1982-11-08	1984-10-09	Abbott Laboratories	Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques
US4476229A (en) *	1982-11-08	1984-10-09	Abbott Laboratories	Substituted carboxyfluoresceins
US4510251A (en) *	1982-11-08	1985-04-09	Abbott Laboratories	Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers
US4681859A (en) *	1984-09-21	1987-07-21	Ortho Diagnostic Systems Inc.	Fluorescence polarization immunoassay for heavy antigens
IL76447A0 (en) *	1984-10-25	1986-01-31	Abbott Lab	Fluorescence polarization assay,reagents,and method of making reagents,for determination of digitoxin
EP0199042A1 (de) *	1985-03-26	1986-10-29	Abbott Laboratories	Probe, Tracers, Immunogene und Antikörper von Procainamid
EP0201751A2 (de) *	1985-05-08	1986-11-20	Abbott Laboratories	4-Aminomethylfluoreszeinderivate zur Verwendung in Fluoreszenz-Polarisationsimmunotesten
EP0218010A3 (de) *	1985-07-10	1988-01-07	Abbott Laboratories	Verfahren zur Bestimmung von Liganden und substituierte Carboxyfluoreszein-Markers zur Durchführung desselben
US4751190A (en) *	1985-07-22	1988-06-14	Abbott Laboratories	Fluorescence polarization immunoassay and reagents for use therein

1986
- 1986-07-14 US US06/885,054 patent/US4939264A/en not_active Expired - Fee Related
1987
- 1987-07-07 EP EP19870109739 patent/EP0254120A3/de not_active Withdrawn
- 1987-07-14 JP JP62174025A patent/JPS6323882A/ja active Pending
1989
- 1989-02-28 US US07/316,846 patent/US5260441A/en not_active Expired - Fee Related

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010505923A (ja) *	2006-10-12	2010-02-25	ネオルフィ	新規なモルヒネ誘導体

Also Published As

Publication number	Publication date
EP0254120A3 (de)	1990-09-12
US4939264A (en)	1990-07-03
US5260441A (en)	1993-11-09
EP0254120A2 (de)	1988-01-27

Publication	Publication Date	Title
JPS6323882A (ja)	1988-02-01	アヘンアルカロイドおよびそれらの代謝物のための免疫検定法、トレ−サ−、免疫原および抗体
EP0279213B1 (de)	1992-10-21	Fluoreszenzpolarisationsimmunassay für Amphetamin/Methamphetamin
EP0108399B1 (de)	1987-09-23	Substituierte Fluorescein-Carbonsäure-Derivate
US4160016A (en)	1979-07-03	Receptor fluorescent immunoassay
US9720004B2 (en)	2017-08-01	Immunoassays employing non-particulate chemiluminescent reagent
EP0399184A2 (de)	1990-11-28	Reagenzien, Verfahren und Testsätze zum Nachweis von Amphetaminen durch einen Fluoreszenz-Polarisations-Immunoassay
EP0218010A2 (de)	1987-04-15	Verfahren zur Bestimmung von Liganden und substituierte Carboxyfluoreszein-Markers zur Durchführung desselben
US5144030A (en)	1992-09-01	Fluorescene polarization immunoassay for tetrahydrocannabinoids
US4952336A (en)	1990-08-28	Fluorescence polymerization immunoassay for amphetamine/methamphetamine
EP0264797B1 (de)	1996-01-10	Test, Indikatoren, Immunogene und Antikörper für Benzodiazepine
EP0371253A2 (de)	1990-06-06	Verfahren und Reagenzien zum Nachweis von Amphetamin und/oder d-Methamphetamin in biologischen Proben
US5463027A (en)	1995-10-31	Fluorescence polarazation immunoassay for tetrahydrocannabinoids
US5124457A (en)	1992-06-23	Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies
EP0199042A1 (de)	1986-10-29	Probe, Tracers, Immunogene und Antikörper von Procainamid
US5202270A (en)	1993-04-13	Cocaine and cocaine metabolites assay tracers, immunogens and antibodies
EP0380019B1 (de)	1995-11-08	Fluoreszenz-Polarisationsimmunoassay für Methadon
EP0200960A1 (de)	1986-11-12	Fluoreszenzpolarisationsimmunoassay auf Gesamtöstriol
EP0226730B1 (de)	1994-03-02	Verbindungen und Immunoassay für tricyclische Antidepressiva
US5258512A (en)	1993-11-02	Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
EP0242847B1 (de)	1993-06-02	Tracer zur Benutzung in immunologischen Fluoreszenz-Polarisationsverfahren zum Nachweis von Flecainid
CA1195995A (en)	1985-10-29	Substituted carboxyfluoresceins
EP0199963B1 (de)	1991-10-23	Probe, Tracers, Immunogene und Antikörper von Ethosuximid
CA2114327C (en)	2003-04-22	Haptens, tracers, immunogens and antibodies for immunoassays for propoxyphene
US5221629A (en)	1993-06-22	Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies
US5336622A (en)	1994-08-09	Tracers for use in flecainide fluorescence polarization immunoassay

JPS6323882A - アヘンアルカロイドおよびそれらの代謝物のための免疫検定法、トレ−サ−、免疫原および抗体 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=25386024

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (34)

Family Cites Families (40)

Cited By (1)

Also Published As

Similar Documents